1. Manufacturers may need additional guidance to ensure consistent calculations of average sales prices Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022 Subject(s): Drug CostsDrug IndustryGovernment RegulationMedicaidMedicare Part BPrescription FeesUnited States
